AI-Driven Clinical Trial Recruitment and Design

The strategic issue

For sponsors, CROs and research sites, the central clinical-development bottleneck is no longer simply whether enough potential participants exist. It is whether trials are designed, activated, and managed so the right patients can be identified, approached, enrolled, and retained without overwhelming sites or eroding patient trust.

The stakeholder themes such as protocol complexity, strict eligibility criteria, site burden, patient understanding, privacy, validation and human oversight are as important in large EHR networks, HIPAA-regulated data flows, FDA expectations for AI credibility, and intense pressure to broaden trial access across community settings. Published benchmarks show why the industry is looking to AI. A systematic review notes that around 80% of trials fail to meet initial enrollment targets and timelines, with costly downstream delays.¹

Tufts CSDD data reported that 53% of studies had extended enrollment timelines, 41% of activated sites under-enrolled, and roughly one in six enrolled volunteers dropped out before completion.² These statistics are not identical measures, but together they point to a consistent problem: recruitment is a system failure, not a marketing failure. AI is useful only if it improves that system.

1. Start with protocol design, not recruitment advertising

Recruitment problems are often embedded months before a first patient is screened. Precision oncology, immunology, rare-disease, and cell-therapy trials increasingly combine biomarker criteria, prior-line constraints, washout periods, laboratory thresholds, imaging schedules, and optional biopsies.

By the time sites receive the protocol, coordinators may need to screen dozens of charts for one eligible patient, and patients may face visit schedules that compete with work, caregiving, and travel realities. AI-enabled feasibility models can stress-test a protocol before finalization.

Natural-language processing (NLP) can parse eligibility criteria; machine-learning models can compare those criteria with de-identified EHR, registry and claims-derived cohorts; and simulation can estimate likely screen-failure drivers, site catchment overlap and visit burden. For example, a Phase II lung-cancer sponsor could model whether an ECOG, hemoglobin or prior-therapy criterion is excluding patients who would otherwise be clinically appropriate, then review alternatives with medical, biostatistics, regulatory, and patient-engagement teams.

AI should not decide eligibility policy, but it can make trade-offs visible early enough to prevent avoidable amendments. More advanced design applications include predictive models for trial success, endpoint selection, and adaptive monitoring.

Research on clinical-trial design has described AI opportunities across cohort selection, patient stratification, endpoint assessment, and operational planning.^3-5 In practice, the near-term value for most organizations is pragmatic: reduce avoidable complexity, quantify feasibility before committing sites, and design visits around patient participation rather than institutional convenience.

2. Use EHR-scale patient matching, but keep clinicians in the loop

The most mature AI use case is patient trial matching. Health systems hold structured data such as diagnosis codes, medications, and labs, but much of the eligibility signal sits in unstructured notes, pathology reports, imaging impressions, and genomic PDFs.

NLP systems can convert that unstructured content into candidate matches and produce a screen-ready list for authorized site staff. Studies of systems such as Watson for Clinical Trial Matching and Trial Eligibility Surveillance System demonstrate the potential of AI-supported eligibility review, while also highlighting the need for validation in context.^6,7

Commercial and provider examples illustrate the market direction. Deep 6 AI describes using AI and NLP over EMR data, including clinician notes, labs, and pathology reports to generate patient cohorts and share matches with research facilities.⁸

The American Hospital Association has highlighted platforms using EHR-based NLP for recruitment and feasibility analytics, including examples reporting faster identification and high accuracy in specific settings.⁹ These examples should be treated as illustrative rather than universally generalizable.

Performance depends on data quality, site workflow, therapeutic area, local documentation habits, and the exact inclusion/exclusion criteria. The operating model matters as much as the algorithm.

A compliant workflow should define who can access identifiable data, when re-identification is permitted, how IRB approvals are structured, how HIPAA authorizations or waivers apply, and how physicians or coordinators verify AI-generated matches. AI-generated lists should be decision support, not automatic recruitment.

The final determination of eligibility, appropriateness and patient outreach must remain with qualified clinical and research personnel.

3. Convert matched patients into participants

Finding candidates is only the top of the funnel. Many trials lose patients during outreach, pre-screening, consent and the first few visits.

AI can support conversion by personalizing education, simplifying visit instructions, flagging likely adherence barriers, and generating plain-language materials for review by medical, legal, and regulatory teams. GenAI can draft versions for different literacy levels or languages, but every patient-facing asset needs human review, version control, and IRB alignment.

Retention is where AI becomes operationally important. Wearables, ePRO/eCOA tools, telehealth visits, smart reminders, and risk-based monitoring can reduce unnecessary site visits and detect adherence or safety signals earlier.

For a cardiovascular outcomes trial, a wearable-enabled monitoring model might flag missing data patterns or physiologic changes that require coordinator follow-up. For a dermatology trial, image capture and ePRO reminders could reduce travel burden.

The principle is patient-centered augmentation: AI should remove friction, not replace the empathy and trust created by investigators and coordinators.

4. Reduce site burden and improve data quality

Clinical research coordinators are often the hidden constraint in trial execution. They screen charts, schedule visits, explain studies, reconcile source data, enter EDC data, answer queries, and maintain binders.

AI-enabled abstraction, automated query triage, source-to-EDC assistance, visit-window forecasting and adverse-event text classification can materially reduce non-clinical workload. That relief can be redirected to patient communication and protocol compliance; however, automation without auditability creates new risks.

Sponsors should require traceable data lineage, source links, confidence scores, exception handling, role-based access, audit trails, and documented human review. If an AI tool summarizes a physician note, the coordinator should be able to see the source phrase.

If a model suggests an adverse-event term, pharmacovigilance staff should know whether it is a recommendation, an extraction, or an autonomous classification. AI must improve data quality without obscuring accountability.

5. Build a ready governance model

The regulatory direction is clearer than many teams assume. FDA’s 2025 draft guidance on AI in drug and biological product development focuses on AI outputs used to support regulatory decision-making and emphasizes a risk-based credibility framework.¹⁰

FDA and EMA’s 2026 good AI practice principles emphasize human-centric design, clear context of use, multidisciplinary expertise, data governance, performance assessment, lifecycle management, and clear essential information.¹¹ FDA’s earlier discussion paper also recognized AI applications across nonclinical, clinical, postmarketing, and manufacturing activities.¹²

For life sciences companies, this means every AI use case should begin with context of use. What question will the model answer? What decision will it influence? What happens if the output is wrong?

A model that ranks sites for feasibility has a different risk profile from one that determines monitoring intensity after dosing. Risk should be assessed by both model influence and decision consequence.

Higher-risk applications require stronger validation, bias analysis, locked specifications, monitoring for drift, and early regulatory engagement. Data governance is equally critical.

AI models trained on unrepresentative data can worsen inequities by missing under-documented patients, underperforming in community settings, or excluding groups with non-standard care patterns. Sponsors should evaluate performance by race, ethnicity, age, sex, geography, language, insurance status where appropriate and legally permissible, and site type.

Privacy and security controls must be designed into the workflow, not added after a vendor demo. HIPAA, informed consent, IRB review, GCP, 21 CFR Part 11 expectations, and cybersecurity requirements all intersect in AI-enabled trials.

6. Economics and data partnerships determine whether AI scales

AI value is realized through redesigned partnerships, not dashboards alone. Most sponsors do not directly control the patient-identifiable data needed for recruitment, but health systems do.

Therefore, scalable implementation requires privacy-preserving data partnerships, clear re-identification rules, data-use agreements, federated or common-data-model approaches where appropriate, and practical support for community sites that lack large informatics teams.

The sponsor’s role is to define the scientific and operational question, fund the workflow, and maintain regulatory-quality evidence. The provider organization’s role is to protect patient relationships and govern outreach.

Vendors should supply model documentation, validation evidence, auditability, and support for change control. The business case should also move beyond model accuracy.

Leaders should track cycle-time and quality metrics such as protocol-amendment avoidance, days from protocol concept to site feasibility decision, charts reviewed per qualified lead, screen-failure rate, first-patient-in timing, enrollment by site type, coordinator hours saved, query volume, visit adherence, dropout rate, and representativeness of enrolled participants. These measures connect AI investment to portfolio economics and patient access.

They also discourage a common failure mode: deploying a technically impressive model that adds another login, another workflow, and another burden to already stretched study teams.

Illustrative example

Consider a mid-sized biotech planning a metastatic non-small cell lung cancer study across academic and community oncology sites. A protocol-feasibility model shows that a restrictive lab threshold and a mandatory on-site biopsy are the largest projected screen-failure drivers.

The team modifies the biopsy requirement, permits a remote safety follow-up visit and pre-specifies rationale in governance documentation. During start-up, an NLP matching tool scans structured EHR data, oncologist notes, and pathology/genomic reports at participating systems.

The model produces a prioritized candidate list with source evidence. CRCs verify each case, treating oncologists decide whether outreach is appropriate, and patients receive IRB-approved plain-language materials.

Performance is monitored monthly for false positives, false negatives, race/ethnicity distribution, age distribution, and site-to-site variation. The point is not that AI replaces the site, but that it makes the site’s scarce time more productive.

What should leaders do now?

Executives should resist two extremes: buying AI as a standalone technology fix or waiting for perfect regulation before experimenting. A practical 12-month roadmap starts with three to five use cases tied to measurable bottlenecks, such as feasibility cycle time, chart-screening hours, screen-failure rate, enrollment diversity, query volume or missed visits.

Establish an AI governance board with clinical operations, data science, biostatistics, regulatory, legal, privacy, quality, pharmacovigilance, patient engagement, and site representatives. Require vendors to provide validation evidence, data provenance, audit functionality, change-control procedures, and contractual clarity on model updates.

Pilots should favor human-in-the-loop decision support before autonomous decision-making. Good starting points include protocol feasibility simulation, EHR pre-screening with coordinator verification, recruitment material personalization with IRB review, visit adherence prediction and automated source-data abstraction.

As confidence grows, organizations can move toward adaptive design support, digital biomarker analytics, and AI-assisted safety monitoring, with regulatory engagement where outputs may support safety, effectiveness, or quality decisions. Portfolio leaders should also define thresholds for stopping or redesigning pilots.

If an EHR-matching model creates too many false positives for coordinators, it should not be scaled merely because it is accurate in retrospective validation. If a chatbot improves response speed but increases escalations, its scope should be narrowed.

If a feasibility model identifies underrepresented communities but the protocol still requires excessive travel, the operating plan—not the algorithm—needs redesign. Treat AI deployment as continuous clinical-operational learning.

Finally, leadership teams should report AI pilots in the same governance rhythm as enrollment, quality, and safety metrics, ensuring that innovation remains tied to trial execution rather than separated into a digital experiment.

Table 1. AI-enabled recruitment and design use cases for sponsors, CROs and sites

Conclusion

AI will not rescue an un-recruitable protocol or compensate for under-resourced sites. It can, however, expose design flaws earlier, identify eligible patients faster, reduce coordinator burden, personalize engagement, and create a more evidence-based operating model for recruitment and retention.

The winners in clinical development will be organizations that treat AI as a regulated, human-centered capability: clinically useful, operationally embedded, privacy-protective, bias-tested, and transparent enough to earn trust from patients, sites, and regulators.

Disclaimer: The views expressed in the article are those of the authors and not of the organizations they represent.

About the Author

Partha Anbil is at the intersection of the Life Sciences industry and Management Consulting. He is currently SVP, Life Sciences, at Coforge Limited, a $2.5B multinational digital solutions and technology consulting services company. He held senior leadership roles at WNS, IBM, Booz & Company, Symphony, IQVIA, KPMG Consulting, and PWC. Mr. Anbil has consulted with and counseled Health and Life Sciences clients on structuring solutions to address strategic, operational, and organizational challenges. He is a diplomat/fellow at MIT CSAIL. He is a healthcare expert member of the World Economic Forum (WEF). He is also a Life Sciences industry advisor at MIT, his alma mater. He was a member of the IBM Industry Academy, a very selective group of professionals inducted into the academy by invitation only, the highest honor at IBM.

References and Sources

1. Brøgger-Mikkelsen M, Aa Bang C, Fjeldborg Hagstrøm S, et al. Online patient recruitment in clinical trials: systematic review and meta-analysis. J Med Internet Res. 2020;22(11):e22179. doi:10.2196/22179
2. Getz K. Enrollment performance: weighing the 'facts.' Applied Clinical Trials. 2012. https://www.appliedclinicaltrialsonline.com/view/enrollment-performance-weighing-facts
3. Harrer S, Shah P, Antony B, Hu J. Artificial intelligence for clinical trial design. Trends Pharmacol Sci. 2019;40(8):577-591. doi:10.1016/j.tips.2019.05.005
4. Fu T, Huang K, Glass L, Zitnik M. HINT: hierarchical interaction network for clinical-trial-outcome predictions. Patterns. 2022;3(4):100445. doi:10.1016/j.patter.2022.100445
5. Zhang B, Tan AC, Bhatt DL. Harnessing artificial intelligence to improve clinical trial design. Commun Med. 2023;3:19. doi:10.1038/s43856-023-00425-3
6. Beck JT, Rammage M, Jackson GP, et al. Artificial intelligence tool for optimizing eligibility screening for clinical trials in a large community cancer center. JCO Clin Cancer Inform. 2020;4:50-59. doi:10.1200/CCI.19.00079
7. Meystre SM, Loehrke A, Cummins M, et al. Piloting an automated clinical trial eligibility surveillance and provider alert system based on artificial intelligence and standard data models. BMC Med Res Methodol. 2023;23:88. doi:10.1186/s12874-023-01916-6
8. Deep 6 AI. Clinical trial recruitment for life sciences using AI. Accessed June 9, 2026. https://deep6.ai/life-sciences/
9. American Hospital Association. How AI is transforming clinical trials. Published October 21, 2025. Accessed June 9, 2026. https://www.aha.org/aha-center-health-innovation-market-scan/2025-10-21-how-ai-transforming-clinical-trials
10. (Duplicate of reference 3 — recommend removing or replacing with a distinct source.)
11. U.S. Food and Drug Administration. Guiding principles of good AI practice in drug development. Updated January 14, 2026. Accessed June 9, 2026. https://www.fda.gov/about-fda/artificial-intelligence-drug-development/guiding-principles-good-ai-practice-drug-development
12. U.S. Food and Drug Administration. Discussion paper and request for feedback: using artificial intelligence and machine learning in the development of drug and biological products. Accessed June 9, 2026. https://www.fda.gov/media/167973/download